Log in

018680 Seoul Pharma Co., Ltd. KRX · South Korea

Seoul Pharma Co. (018680) news

Seoul Pharma Co., Ltd. is a public biotech or pharmaceutical company listed on KRX under the ticker 018680, recorded under South Korea. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Seoul Pharma Co. news

We have not published a story on Seoul Pharma Co. yet. When there is news, it will appear here.

Questions about Seoul Pharma Co.

What is the ticker symbol of Seoul Pharma Co.?

Seoul Pharma Co., Ltd. trades under the ticker 018680 on KRX.

Where is Seoul Pharma Co. listed?

Seoul Pharma Co., Ltd. is listed on KRX.

Which country or territory is Seoul Pharma Co. listed under?

Our directory records Seoul Pharma Co., Ltd. under South Korea.

What does Seoul Pharma Co. do?

Our directory classifies Seoul Pharma Co., Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Seoul Pharma Co.?

The ISIN recorded for Seoul Pharma Co., Ltd. is KR7018680009.

Does aibio.space cover Seoul Pharma Co.?

aibio.space lists Seoul Pharma Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Seoul Pharma Co.?

Companies in our directory listed in the same country and business area as Seoul Pharma Co.: Genome & Co., KOREA PHARMA Co., TASCOM Co.,Ltd., SAMSUNG PHARMACEUTICAL.CO.,Ltd., Theragen Etex Co., D&D Pharmatech Co..

Investor discussion: Seoul Pharma Co.

Members talk about Seoul Pharma Co. (018680). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open KRX:018680 on TradingView.

Listing details

Seoul Pharma Co., Ltd. is a public biotech or pharmaceutical company listed on KRX under the ticker 018680, recorded under South Korea. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Seoul Pharma Co., Ltd.
Ticker
018680
Listing
KRX
Country or territory
South Korea
Business scope
Pharmaceuticals: Major
ISIN
KR7018680009
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.